| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP & CFO | SVP & General Counsel
1 company
Gregory O. Anglum last filed a Form 4 in February 2022, as SVP & CFO at BVS. Gregory O. Anglum's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 55,013 shares of BVS. Net of sales, the BVS filings show accumulation of 4,706 shares.
Gregory O. Anglum has 4 Form 4 filings on record from February 2021 to February 2022, all as SVP & CFO at Bioventus (BVS), 2021–2022.
The 8 reported transactions were 3 option or other derivative awards, 2 option exercises, 1 open-market sale and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $78K and 1 sale worth about $16K.
The only open-market purchase was 6,000 shares of BVS at an average $13.00 on February 11, 2021, about $78K.
The only open-market sale was 1,294 shares of BVS at an average $11.99 on February 14, 2022, about $16K. Twelve months later BVS was down 86%.
Shares as reported in the last Form 4 for each company; the most recent is from February 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.